BJMO - volume 19, issue 1, january 2025
L. Seynaeve MD
Neurological diseases occur more frequently in patients with active tumours and/or undergoing treatment for oncological disease. Malignancy-associated changes in cell signalling and biological processes occur, as well as “naturally occurring” and treatment-induced immune-related adverse events that can be both cell- or antibody-mediated. Prompt evaluation, timely accurate treatment, and interdisciplinary care are of paramount importance to prevent or diminish long-term neurological sequelae and mortality.
(BELG J MED ONCOL 2025;19(1):11–14)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
